1 Min Read
Aug 3 (Reuters) - Roche Holding AG:
* PRIME DESIGNATION GRANTED BY EUROPEAN MEDICINES AGENCY FOR RG6042 FOR TREATMENT OF HUNTINGTON’S DISEASE Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.